Brief: Resmed Q4 Adjusted EPS USD 2.08 Vs. IBES Estimate USD 2.07
01/08/2024 21:05
Aug 01 (Reuters) - Resmed Q4 EPS USD 1.98. * Q4 revenue USD 1,200 million vs. IBES estimate USD 1,217 million * Q4 adjusted gross margin 59.1% * Q4 gross margin 58.5%
Recent news on ResMed
See all newsCiti lifts ResMed's ASX-listed stock's target price after FX, valuation updates
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
Brief: Resmed - Enters Accelerated Share Repurchase Agreement To Repurchase $450 Million Of Common Stock - SEC Filing
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT